IDEAYA Biosciences (IDYA) Income from Continuing Operations (2018 - 2026)

IDEAYA Biosciences has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 108544000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 108544000.0, down 28.62% year-over-year; the trailing twelve-month figure through Mar 2026 was 183468000.0 (up 49.09% YoY), and the FY2025 annual result was 159313000.0, up 51.28% from the prior year.
• Income from Continuing Operations came in at 108544000.0 for Q1 2026 at IDEAYA Biosciences, down from 94570000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 108452000.0 in Q3 2025 to a low of 144138000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 41917000.0 (2023), against an average of 46574411.76.
• Across the five-year window, Income from Continuing Operations slumped 5179.7% in 2023 and surged 262.13% in 2025, its largest moves.
• IDEAYA Biosciences' Income from Continuing Operations stood at 26443000.0 in 2022, then tumbled by 58.52% to 41917000.0 in 2023, then slumped by 243.87% to 144138000.0 in 2024, then soared by 34.39% to 94570000.0 in 2025, then fell by 14.78% to 108544000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 108544000.0 (Q1 2026), 94570000.0 (Q4 2025), and 108452000.0 (Q3 2025), per Business Quant data.